<DOC>
	<DOCNO>NCT02762994</DOCNO>
	<brief_summary>BCD-085-2 next step clinical investigation BCD-085 . BCD-085 monoclonal antibody interleukin 17 . During BCD-085-2 trial patient moderate severe plaque psoriasis , poor response previous treatment include UV-therapy biologic drug register , receive 40 , 80 120 mg BCD-085 subcutaneously week 0 , 1 , 2 , 4 , 6 , 8 , 10 . Efficacy safety parameter evaluate .</brief_summary>
	<brief_title>International Clinical Trial Evaluate Efficacy Safety Multiple Subcutaneous Injections BCD-085 Various Doses Patients With Moderate Severe Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Written inform consent Age 18 65 year Diagnosis plaque psoriasis stable course disease last 6 month prior enrollment study . Patient least 1 course phototherapy systemic therapy psoriasis candidate treatment . BSA affect psoriasis ≥ 10 % , PASI score ≥ 12 , sPGA score ≥ 3 . If patient biologic therapy least 3 month , positive result treatment patient reveal intolerance drug . This therapy must discontinue least 12 week enrollment study . Female patient negative urine pregnancy test . Patient history tuberculosis . Patients negative result Diaskintest . Patient history alcohol drug abuse . Patients able perform procedure plan protocol . Patients ready contraception reliable method start 2 week enter study , 4 week last dose study drug . Subject diagnose erythrodermic psoriasis , pustular psoriasis , guttate psoriasis , medicationinduced psoriasis , skin condition time screen visit ( e.g. , eczema ) would interfere evaluation effect investigational product psoriasis . Previous receipt antiinterleukin 17 drug antiinterleukin 17 receptor drug . Prior use two biologics tumor necrosis factor alfa . Prior use two biologics target . Previous receipt monoclonal antibody cancel less 12 week sign informed consent . Patient take corticosteroid 4 week dose 10 mg ( recalculate prednisolone ) signing informed consent screening , dose less 10 mg ( recalculate prednisolone ) stable . Prior use diseasemodifying drug include methotrexate , sulfasalazin cyclosporin 4 week sign informed consent , dose stable 4 week sign informed consent screen Prior use live attenuate vaccine 8 week sign informed consent . Prior use phototherapy include selective phototherapy photochemotherapy 4 week sign informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>interleukin 17</keyword>
	<keyword>monoclonal antibody</keyword>
	<keyword>psoriasis</keyword>
</DOC>